ADD/ADHD News

The FDA has cleared NeuroSigma’s second-generation Monarch eTNS System for treatment of pediatric ADHD, the company announced in a press release.

Some of the most-viewed stories on Healio Psychiatry over the past year highlighted the FDA designating an at-home depression treatment as a breakthrough device as well as the transformative power of psychedelics.

Keratoconus may be associated with ADHD in male patients, according to a study recently published in JAMA Ophthalmology.

Otsuka Pharmaceutical has announced positive outcomes from two 6-week phase 3 clinical trials testing the safety and efficacy of centanafadine for the treatment of ADHD, according to a press release.

ADHD-related medication errors increased almost 300% from 2000 to 2021 among people aged younger than 20 years, a study found.

Amneal Pharmaceuticals has received an abbreviated new drug application from the FDA for its lisdexamfetamine dimesylate capsules to treat ADHD in patients aged 6 years and older and moderate to severe binge-eating disorder in adults.

The FDA has approved multiple first generics of Vyvanse capsules and chewable tablets for ADHD in patients aged 6 years and older, as well as for moderate to severe binge-eating disorder in adults.

Young adults who used prescription stimulants as children were not more likely than their peers to use illicit drugs later on, according to a study published in JAMA Network Open.

Stimulant treatment for ADHD is not associated with substance use in adolescence and early adulthood, according to a study published in JAMA Psychiatry.

Children born to placentas with fetal inflammatory syndrome are more likely to be diagnosed with neuropsychiatric disorders, according to a study published in Translational Psychiatry.